<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099003</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2021-11337</org_study_id>
    <secondary_id>NCI-2021-11337</secondary_id>
    <secondary_id>ACNS1821</secondary_id>
    <secondary_id>ACNS1821</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT05099003</nct_id>
  </id_info>
  <brief_title>A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma</brief_title>
  <official_title>A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and H3 K27M-Mutant High-Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1/2 trial tests the safety, side effects, and best dose and whether selinexor and&#xD;
      radiation therapy work in treating patients with newly-diagnosed diffuse intrinsic pontine&#xD;
      glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. A&#xD;
      glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk&#xD;
      (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the&#xD;
      chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the&#xD;
      pons (a part of the brainstem that controls functions like breathing, swallowing, speaking,&#xD;
      and eye movements). Selinexor may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Radiation therapy uses high energy to kill tumor cells and&#xD;
      shrink tumors. Selinexor and radiation therapy together may be a beneficial treatment for&#xD;
      DIPG and H3 K27M-mutant HGG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2&#xD;
      dose (RP2D) of selinexor administered as an oral formulation in combination with standard of&#xD;
      care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma&#xD;
      (HGG) or diffuse intrinsic pontine glioma (DIPG).(Dose-finding phase) II. To estimate the&#xD;
      event-free survival (EFS) distribution for diffuse midline glioma, H3 K27M-mutant (DMG)/HGG&#xD;
      patients and overall survival (OS) distribution for DIPG patients associated with selinexor&#xD;
      plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3&#xD;
      K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy&#xD;
      phase)&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future&#xD;
      studies.&#xD;
&#xD;
      OUTLINE: This is a phase 1 dose-escalation study of selinexor followed by a phase 2 study.&#xD;
&#xD;
      CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for&#xD;
      5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally&#xD;
      (PO) on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or&#xD;
      unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance.&#xD;
&#xD;
      MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Treatment&#xD;
      repeats every 28 days for up to 24 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for year 1 (i.e.,&#xD;
      3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and&#xD;
      finally once yearly for years 4-5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>From the date of diagnosis until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years</time_frame>
    <description>EFS curve will be estimated by Kaplan Meier estimates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of diagnosis until death date of any cause or last follow-up date, assessed up to 5 years.</time_frame>
    <description>The OS curve will be estimated by Kaplan Meier estimates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ORR is defined as the proportion of patients whose best response is partial response or complete response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Diffuse Midline Glioma, H3 K27M-Mutant</condition>
  <condition>Glioblastoma</condition>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Treatment (selinexor and radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance.&#xD;
MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (selinexor and radiation therapy)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>ENERGY_TYPE</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (selinexor and radiation therapy)</arm_group_label>
    <other_name>ATG-010</other_name>
    <other_name>CRM1 Nuclear Export Inhibitor KPT-330</other_name>
    <other_name>KPT-330</other_name>
    <other_name>Selective Inhibitor of Nuclear Export KPT-330</other_name>
    <other_name>SINE KPT-330</other_name>
    <other_name>Xpovio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  STEP 0: Patients must be &gt;= 12 months and =&lt; 25 years of age (non-pontine tumors) OR&#xD;
             &gt;= 12 months and =&lt; 21 years of age (DIPG) at the time of enrollment on Step 0.&#xD;
&#xD;
               -  Please note:&#xD;
&#xD;
                    -  This age range includes pre-screening for all HGG patients. Individual&#xD;
                       treatment protocols may have different age criteria.&#xD;
&#xD;
                    -  Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are&#xD;
                       &gt;= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1).&#xD;
&#xD;
          -  STEP 0: Patient is suspected of having localized, newly diagnosed HGG, excluding&#xD;
             metastatic disease, OR patient has an institutional diagnosis of DIPG&#xD;
&#xD;
          -  STEP 1: Patients must be &gt;= 12 months and =&lt; 21 years of age at the time of enrollment&#xD;
&#xD;
          -  STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG).&#xD;
&#xD;
          -  STEP 1: Stratum DMG (with H3 K27M mutation)&#xD;
&#xD;
               -  Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without&#xD;
                  BRAF^V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular&#xD;
                  Screening Reviews performed on APEC14B1&#xD;
&#xD;
               -  Note: Patients need not have either measurable or evaluable disease, i.e., DMG&#xD;
                  patients may have complete resection of their tumor prior to enrollment. Primary&#xD;
                  spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in&#xD;
                  non-midline structures (e.g., cerebral hemispheres), these patients will be&#xD;
                  considered part of Stratum DMG.&#xD;
&#xD;
          -  STEP 1: Stratum HGG (without H3 K27M mutation)&#xD;
&#xD;
               -  Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without&#xD;
                  BRAF^V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular&#xD;
                  Screening Reviews performed on APEC14B1&#xD;
&#xD;
               -  Please note:&#xD;
&#xD;
                    -  Patients who fall in this category and who are â‰¥ 18 years of age are not&#xD;
                       eligible due to another standard-of-care regimen (radiation/temozolomide)&#xD;
                       that is available&#xD;
&#xD;
                    -  Patients need not have either measurable or evaluable disease, i.e., HGG&#xD;
                       patients may have complete resection of their tumor prior to enrollment.&#xD;
                       Primary spinal tumors are eligible for enrollment&#xD;
&#xD;
          -  STEP 1: Patients must have a performance status corresponding to Eastern Cooperative&#xD;
             Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients &gt; 16 years of&#xD;
             age and Lansky for patients =&lt;16 years of age. Patients who are unable to walk because&#xD;
             of paralysis, but who are up in a wheelchair, will be considered ambulatory for the&#xD;
             purpose of assessing the performance score.&#xD;
&#xD;
          -  STEP 1: Peripheral absolute neutrophil count (ANC) &gt;= 1000/uL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/uL (transfusion independent)&#xD;
&#xD;
          -  STEP 1: Hemoglobin &gt;= 8.0 g/dL (may receive red blood cell [RBC] transfusions)&#xD;
&#xD;
          -  STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             mL/min/1.73 m^2 or&#xD;
&#xD;
          -  STEP 1: A serum creatinine based on age/gender as follows:&#xD;
&#xD;
               -  Age / Maximum Serum Creatinine (mg/dL)&#xD;
&#xD;
                    -  1 to &lt; 2 years / male: 0.6; female: 0.6&#xD;
&#xD;
                    -  2 to &lt; 6 years / male: 0.8; female: 0.8&#xD;
&#xD;
                    -  6 to &lt; 10 years / male: 1; female: 1&#xD;
&#xD;
                    -  10 to &lt; 13 years / male: 1.2; female: 1.2&#xD;
&#xD;
                    -  13 to &lt; 16 years / male: 1.5; female: 1.4&#xD;
&#xD;
                    -  &gt;= 16 years / male: 1.7; female: 1.4&#xD;
&#xD;
          -  STEP 1: Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age&#xD;
&#xD;
          -  STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT])&#xD;
             =&lt; 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.&#xD;
&#xD;
          -  STEP 1: Serum amylase =&lt; 1.5 x ULN&#xD;
&#xD;
          -  STEP 1: Serum lipase =&lt; 1.5 x ULN&#xD;
&#xD;
          -  STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry&#xD;
             &gt; 94% if there is clinical indication for determination.&#xD;
&#xD;
          -  STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants and well&#xD;
             controlled.&#xD;
&#xD;
          -  STEP 1: Patients must be enrolled and protocol therapy must begin no later than 31&#xD;
             days after the date of radiographic diagnosis (in the case of non-biopsied DIPG&#xD;
             patients only) or definitive surgery, whichever is the later date (Day 0).&#xD;
&#xD;
        For patients who have a biopsy followed by resection, the date of resection will be&#xD;
        considered the date of definitive diagnostic surgery. If a biopsy only was performed, the&#xD;
        biopsy date will be considered the date of definitive diagnostic surgery.&#xD;
&#xD;
          -  STEP 0:&#xD;
&#xD;
               -  For patients with non-pontine tumors: Patient and/or their parents or legal&#xD;
                  guardians have signed informed consent for eligibility screening on APEC14B1 Part&#xD;
                  A.&#xD;
&#xD;
               -  For patients with DIPG: Patient and/or their parents or legal guardians have&#xD;
                  signed informed consent for ACNS1821.&#xD;
&#xD;
          -  STEP 1: Stratum DIPG&#xD;
&#xD;
               -  Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine&#xD;
                  epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial&#xD;
                  T2 weighted image, are eligible. No histologic confirmation is required.&#xD;
&#xD;
               -  Patients with pontine tumors that do not meet radiographic criteria for typical&#xD;
                  DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine&#xD;
                  cross-sectional area with or without extrapontine extension) are eligible if the&#xD;
                  tumors are biopsied and proven to be high-grade gliomas (such as anaplastic&#xD;
                  astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS],&#xD;
                  and/or H3 K27M-mutant) by institutional diagnosis.&#xD;
&#xD;
          -  STEP 1: All patients and/or their parents or legal guardians must sign a written&#xD;
             informed consent&#xD;
&#xD;
          -  STEP 1: All institutional, Food and Drug Administration (FDA), and National Cancer&#xD;
             Institute (NCI) requirements for human studies must be met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  STEP 1: Patients must not have received any prior therapy for their central nervous&#xD;
             system (CNS) malignancy except for surgery and steroid medications.&#xD;
&#xD;
          -  STEP 1: Patients who are currently receiving another investigational drug are not&#xD;
             eligible.&#xD;
&#xD;
          -  STEP 1: Patients who are currently receiving other anti-cancer agents are not&#xD;
             eligible.&#xD;
&#xD;
          -  STEP 1: Patients &gt;=18 years of age who have H3 K27M-wild type HGG.&#xD;
&#xD;
          -  STEP 1: Patients who have an uncontrolled infection.&#xD;
&#xD;
          -  STEP 1: Patients who have received a prior solid organ transplantation.&#xD;
&#xD;
          -  STEP 1: Patients with Grade &gt; 1 extrapyramidal movement disorder.&#xD;
&#xD;
          -  STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts.&#xD;
&#xD;
          -  STEP 1: Patients with metastatic disease are not eligible; magnetic resonance imaging&#xD;
             (MRI) of spine with and without contrast must be performed if metastatic disease is&#xD;
             suspected by the treating physician.&#xD;
&#xD;
          -  STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the&#xD;
             exception of H3 K27M-mutant bithalamic tumors.&#xD;
&#xD;
          -  STEP 1: Patients who are not able to receive protocol specified radiation therapy.&#xD;
&#xD;
          -  STEP 1:&#xD;
&#xD;
               -  Female patients who are pregnant are ineligible since there is yet no available&#xD;
                  information regarding human fetal or teratogenic toxicities.&#xD;
&#xD;
               -  Lactating females are not eligible unless they have agreed not to breastfeed&#xD;
                  their infants. It is not known whether selinexor is excreted in human milk.&#xD;
&#xD;
               -  Female patients of childbearing potential are not eligible unless a negative&#xD;
                  pregnancy test result has been obtained.&#xD;
&#xD;
               -  Sexually active patients of reproductive potential are not eligible unless they&#xD;
                  have agreed to use two effective methods of birth control (including a medically&#xD;
                  accepted barrier method of contraception, e.g., male or female condom) for the&#xD;
                  duration of their study participation and for 90 days after the last dose of&#xD;
                  selinexor. Abstinence is an acceptable method of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam L Green</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Adam L. Green</last_name>
      <phone>303-724-8786</phone>
      <email>adam.green@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Adam L. Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Diffuse Intrinsic Pontine Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

